Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 972 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Growth colony stimulating factor (G-CSF) Clear all
Completed Phase 3 Interventional Results available

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

NCT00450450
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
Interventions
allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
Procedure · Other · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
21
States / cities
Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

NCT02923791
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Filgrastim Hospira, US-Approved Neupogen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Coral Gables, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

NCT00304083
View directory record Official record
Conditions
Neurofibromatosis Type 1, Sarcoma
Interventions
filgrastim, doxorubicin hydrochloride, etoposide, ifosfamide, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
View directory record Official record
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients

NCT00001272
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
taxol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

NCT03012672
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

NCT00070304
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
View directory record Official record
Conditions
Multiple Myeloma, Leukemia, Plasma Cell
Interventions
Carfilzomib, Melphalan, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

NCT00021333
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

NCT00068393
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
Interventions
Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neulasta
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
92
States / cities
Los Angeles, California • Aurora, Colorado • Aurora, Illinois + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00005964
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 3 Interventional Results available

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

NCT01445821
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Peripheral Blood Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, Filgrastim, Fludarabine
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 1 Interventional

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

NCT00520468
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Erythropoietin, Cyclosporin A, G-CSF, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

NCT00053118
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
Interventions
filgrastim, carboplatin, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
3
States / cities
St Louis, Missouri • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Sep 30, 2026, 8:33 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

NCT02835794
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Omacetaxine, Azacitidine, G-CSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

NCT00630253
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

NCT00005087
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 30, 2026, 8:33 AM EDT
Withdrawn Phase 1 Interventional

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06007911
View directory record Official record
Conditions
Relapsed Adult AML, Refractory AML
Interventions
Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 30, 2026, 8:33 AM EDT
Withdrawn Phase 2 Interventional

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

NCT02587871
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Interventions
Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, G-CSF mobilized peripheral blood cells
Drug · Other · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
Up to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

G-CSF for Granulocyte Donation

NCT00001842
View directory record Official record
Conditions
Healthy
Interventions
Granulocyte colony-stimulating factor, Dexamethasone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

NCT00041470
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Vinorelbine, Herceptin, Filgrastim
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 30, 2026, 8:33 AM EDT